Pharma contact center market seen topping $5.1 billion by 2030

The global market for contact centers serving pharmaceutical companies is projected to grow from $2.95 billion in 2025 to $5.1 billion by 2030, driven by clinical trial activity, biologic drugs and patient support needs. North America led in 2025, while Asia-Pacific is forecast to grow the fastest.

Why it matters: - Pharma companies are leaning more on specialized contact centers to manage customer support, safety reporting and patient engagement. - The market's forecast growth points to stronger demand for outsourced, compliant communication tools across the drug lifecycle. - The shift matters because contact centers now sit at the intersection of regulatory obligations, clinical operations and patient care.

What happened: - The Business Research Company projected the global contact centers for pharma market will rise from $2.95 billion in 2025 to $3.29 billion in 2026. - The firm forecast the market will reach $5.1 billion by 2030. - The report said the market is growing at a 11.3% CAGR in the near term and an 11.6% CAGR through 2030. - The market report was released July 16, 2026. - The source report is available as a free sample and the full report.

The details: - Contact centers for pharma handle inbound and outbound interactions with healthcare professionals, patients and regulators. - Core functions include medical inquiries, patient support, adverse event reporting, appointment scheduling and product information delivery. - The market's recent growth was tied to centralized support operations, adverse event reporting requirements, global pharma commercialization, outsourcing of non-core communication services and basic CRM adoption. - Future growth is expected to come from AI-powered conversational agents, virtual assistants, cloud-based infrastructure, patient-centric care models, real-time pharmacovigilance and advanced analytics. - Key trends include AI-driven omnichannel automation, intelligent call routing, cloud-enabled patient support platforms, integrated safety monitoring, personalized communication and virtual medical information services. - The report said clinical trial expansion is a major driver because contact centers help coordinate researchers, participants and providers. - ABPI reported in December 2024 that UK pharmaceutical trials increased from 411 in 2022 to 426 in 2023. - Specialty and biologic drugs are also expanding the market because they require more patient education, adherence support and therapy coordination. - WHO said in February 2025 that the 2023 Essential Medicines List includes 81 biologic therapies, representing more than 15% of listed medicines. - Patient support programs are another growth driver because they help patients access and manage treatment. - HRSA said in August 2024 that HRSA-funded health centers served more than 31 million patients in 2023. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region. - The analysis also covered South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a broader push by drugmakers to professionalize patient communication as therapies become more complex. - AI and cloud adoption suggest the market is moving from basic call handling toward more automated, data-driven support. - Clinical trial growth and biologics adoption show that demand is coming from both development-stage work and ongoing treatment support.

What's next: - Market momentum will likely track adoption of AI-enabled support tools and cloud platforms. - Regional growth may shift toward Asia-Pacific as healthcare access expands and pharma commercialization accelerates. - Pharma contact centers will likely play a larger role in pharmacovigilance, patient services and remote medical information support.

The bottom line: - Pharma contact centers are moving from back-office support to a core operational layer, and the market could nearly double to $5.1 billion by 2030.